Morgan Stanley downgraded Personalis from Overweight to Equal-Weight and set a new price target of $25.00 from $32.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/17/2025 | $8.00 | Buy | Canaccord Genuity |
| 2/6/2023 | $8.00 | Hold → Buy | Needham |
| 2/6/2023 | Hold → Buy | Needham | |
| 2/25/2022 | $30.00 → $24.00 | Outperform | Oppenheimer |
| 2/25/2022 | $30.00 → $18.00 | Buy | Citigroup |
| 2/25/2022 | $50.00 → $38.00 | Buy | HC Wainwright & Co. |
| 1/7/2022 | $27.00 → $23.00 | Neutral → Buy | BofA Securities |
| 11/8/2021 | $32.00 → $25.00 | Overweight → Equal-Weight | Morgan Stanley |
Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se
Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011. Effective December 31, 2022, Aaron Tachibana, Personalis Chief Financial Officer, will serve as interim CEO and Christopher Hall, Personalis SVP and Head, Diagnostics Business, will be promoted to President. Mr. West will continue to serve as an advisor to the Board. "We th
Canaccord Genuity initiated coverage of Personalis with a rating of Buy and set a new price target of $8.00
Needham upgraded Personalis from Hold to Buy and set a new price target of $8.00
Needham upgraded Personalis from Hold to Buy
Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis' technology Highlighted compelling performance of NeXT Personal for resectable Stage I-IV colorectal cancer (CRC) in a study
100% of resectable Stage I-IV colorectal cancer relapses were detected ahead of imaging, with 87% of those relapses having been detected in the first eight weeks following surgery Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced new interim analysis results of the VICTORI study showing strong performance of its ultra-sensitive NeXT Personal assay in detecting early signs of residual or recurrent colorectal cancer (CRC). The study, led by Dr. Jonathan Loree's team at BC Cancer in Vancouver, Canada, utilized NeXT Personal to look for small traces of circulating tumor DNA (ctDNA) in blood samples from a cohort of 71 patients with resecta
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusio
Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis' technology Highlighted compelling performance of NeXT Personal for resectable Stage I-IV colorectal cancer (CRC) in a study
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusio
Full year revenue of $84.6 million represents a 15% year-over-year increase Cash balance of $185 million expected to provide runway to cash flow break-even Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights. Recent Business Highlights Delivered 1,441 total molecular tests in the fourth quarter of 2024, an increase of 52% compared with 945 tests delivered in the third quarter of 2024; delivered 3,285 total molecular tests for the full year of 2024 compared with 177 in 2023 Submitted for Medicare coverage in early
SC 13G/A - Personalis, Inc. (0001527753) (Subject)
SC 13G - Personalis, Inc. (0001527753) (Subject)
SC 13D/A - Personalis, Inc. (0001527753) (Subject)
4 - Personalis, Inc. (0001527753) (Issuer)
10-Q - Personalis, Inc. (0001527753) (Filer)
8-K - Personalis, Inc. (0001527753) (Filer)
EFFECT - Personalis, Inc. (0001527753) (Filer)
4 - Personalis, Inc. (0001527753) (Issuer)
4 - Personalis, Inc. (0001527753) (Issuer)
4 - Personalis, Inc. (0001527753) (Issuer)